Single Dose Study of ALZ-801 Prototype Tablets

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-16

Study Completion Date

2015-11-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase 1, single-center, open-label, non-randomized, sequential single dose 4-period study in 12 healthy subjects to assess the pharmacokinetics of ALZ-801, tramiprosate and the primary metabolite of tramiprosate, NRM5074, from prototype drug product formulations of ALZ-801, and to assess effect of food on the bioavailability of ALZ-801 and tramiprosate of the prototype tablet formulation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers

NCT04570644

Healthy Volunteers Alzheimer Disease

COMPLETED PHASE1

Multiple Ascending Dose Study of ALZ-801

NCT04157712

Alzheimer Disease

COMPLETED PHASE1

A Phase I Study for Safety and Tolerability of AL002.

NCT03635047

Healthy Alzheimer Disease

COMPLETED PHASE1

A Study of NH280105 in Healthy Adult Participants

NCT06870058

Alzheimer Disease

COMPLETED PHASE1

Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects

NCT05363293

Alzheimer's Disease Healthy Non-elderly and Elderly Adults

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single-center, open-label, non-randomized, sequential, single-dose, 4-period study in 12 healthy adult subjects. Subjects are to receive a single oral dose of ALZ-801 in each of the 4 study periods (Regimens A, B, C and D) in a non-randomized, sequential manner, separated by a minimum washout period of 7 days. The washout period is expected to last approximately 14 days to permit interim decisions to take place and to allow for the selection of the formulation of the subsequent regimen. Periods of interim analysis will take place following dosing with prototype formulations Regimens A, B, and C, during which the PK and safety data are reviewed to determine the dose to be administered in the subsequent treatment period. Interim decisions aim to identify a prototype ALZ-801 immediate release tablet formulation that provides a similar tramiprosate AUC and Cmax to that of historical values after administration of a 100 mg loose-filled tramiprosate capsule in the fasted state.

Optimization of the required tramiprosate exposure will be made by adjusting the dose of ALZ-801 in the prototype tablets using a formulation design space with a target dose range, per tablet, of 171 to 514 mg ALZ-801 (equivalent to 100 mg to 300 mg tramiprosate). Dose selection will be made after a complete review of all data collected from the previous dose group. For dose selection to occur, data is required to be available from a minimum of 8 evaluable subjects with complete safety assessments up to 24 h post-dose, and required safety and PK data (AEs, plasma concentrations of ALZ-801, tramiprosate and NRM5074, and Tmax, Cmax and AUC estimates for ALZ-801 and tramiprosate).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Subjects were to receive a single oral dose of ALZ-801 in each of the 4 study periods (Regimens A, B, C and D) in a non-randomized, sequential manner, separated by a minimum washout period of 7 days.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Regimen A

ALZ-801 171 mg tablet, fasting, once

Group Type EXPERIMENTAL

ALZ-801 170 mg Fasting

Intervention Type DRUG

Regimen B

ALZ-801 205 mg tablet, fasting, once

Group Type EXPERIMENTAL

ALZ-801 205 mg Fasting

Intervention Type DRUG

Regimen C

ALZ-801 205 mg tablet, after food once

Group Type EXPERIMENTAL

ALZ-801 205 mg After Food

Intervention Type DRUG

Regimen D

ALZ-801 342 mg (administered as 2 x 171 mg tablets of ALZ-801), after food, once

Group Type EXPERIMENTAL

ALZ-801 342 mg Fasting

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ALZ-801 170 mg Fasting

Intervention Type DRUG

ALZ-801 205 mg Fasting

Intervention Type DRUG

ALZ-801 205 mg After Food

Intervention Type DRUG

ALZ-801 342 mg Fasting

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy males and females
* Females must be of non-childbearing potential
* Body mass index (BMI) of 18.0 to 35.0 kg/m2

Exclusion Criteria

* History of any drug or alcohol abuse in the past 2 years
* Subjects known to have a creatinine clearance of \<60 mL/min
* Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
* History of cardiovascular, renal, hepatic, neurological, psychiatric, chronic respiratory or gastrointestinal disease as judged by the investigator

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes